|
|
Volumn 3, Issue 1, 2001, Pages 1-2
|
|
The other side of TNF-targeted therapy of patients with rheumatoid arthritis.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIRHEUMATIC AGENT;
INFLIXIMAB;
METHOTREXATE;
MONOCLONAL ANTIBODY;
TUMOR NECROSIS FACTOR ALPHA;
ARTICLE;
DOSE RESPONSE;
DRUG EFFECT;
HUMAN;
JAPAN;
MULTICENTER STUDY;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
RHEUMATOID ARTHRITIS;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
DOSE-RESPONSE RELATIONSHIP, DRUG;
HUMANS;
JAPAN;
METHOTREXATE;
MULTICENTER STUDIES;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0035259721
PISSN: 15233774
EISSN: None
Source Type: Journal
DOI: 10.1007/s11926-001-0041-2 Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|
